Dr. T. Alp Ikizler
Dr. T. Alp Ikizler is currently Catherine McLaughlin Hakim Chair in Vascular Biology and Professor of Medicine at the Vanderbilt University School of Medicine in Nashville, Tennessee. He is the Associate Director of Division of Nephrology and he also directs the Master of Science in Clinical Investigation Program, the most prominent educational platforms for Clinical Translational Research at Vanderbilt University. He is Past President of International Society of Renal Nutrition and Metabolism. Dr. Ikizler received his medical degree from the Istanbul University Faculty of Medicine where he completed his internships and internal medicine residency. His research group aims to examine the factors that lead to adverse clinical outcomes in patients with kidney disease, a population at significantly increased risk of hospitalization and death. The primary research interest of the Ikizler Lab is nutritional and metabolic aspects of kidney disease with a special interest in inflammation and oxidative stress. His group also conducts studies testing the effects of antioxidant and anti-inflammatory therapies on oxidative stress, inflammation, and endothelium dependent vascular function in CKD patients. Acute kidney injury (AKI) is also one of their primary research interests. Dr. Ikizler’s initial studies explored the quantification of dialytic therapy in the AKI patients. Over the last 10 years, Vanderbilt University Medical Center has been a part of large clinical studies in AKI patients under the local leadership of Dr. Ikizler. One of these studies (PICARD) was performed at 5 institutions and included 618 subjects in the ICU with established AKI, with 398 requiring renal replacement therapy and includes the most comprehensive phenotyping of similar patient cohorts. With the availability of VALID study, they expanded their interest to biomarker validation in the ICU setting. Dr. Ikizler research group is also collaborating with the Biomedical Informatics faculty at VUMC to develop electronic medical record based risk stratification models and AKI prevention strategies to improve the health care delivery to patients with AKI. These activities have allowed them to participate in the ASSESS-AKI as a clinical site since its inception.